The Manufacturers Life Insurance Company Invests $1.30 Million in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• The Manufacturers Life Insurance Company acquired 27,907 shares of Supernus Pharmaceuticals worth approximately $1.30 million during the second quarter.
• Several other institutional investors also initiated positions in Supernus, while analyst sentiment remained mixed but leaned positive, with an overall “Moderate Buy” rating and an average price target of $62.83.
• Supernus reported quarterly revenue of $219.06 million, up 32.4% year over year and above estimates, but missed earnings expectations with a loss of $1.01 per share.

The Manufacturers Life Insurance Company acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 27,907 shares of the specialty pharmaceutical company's stock, valued at approximately $1,298,000.

Several other hedge funds and other institutional investors have also made changes to their positions in SUPN. Algert Global LLC purchased a new stake in Supernus Pharmaceuticals during the second quarter worth approximately $4,236,000. Commerce Bank purchased a new position in Supernus Pharmaceuticals in the second quarter valued at approximately $588,000. Quantbot Technologies LP purchased a new position in Supernus Pharmaceuticals in the second quarter valued at approximately $2,219,000. Allworth Financial LP acquired a new stake in Supernus Pharmaceuticals during the second quarter worth approximately $2,357,000. Finally, NFJ Investment Group LLC acquired a new stake in Supernus Pharmaceuticals during the second quarter worth approximately $2,455,000.

Analyst Upgrades and Downgrades

SUPN has been the subject of several research analyst reports. Wall Street Zen cut shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Weiss Ratings reiterated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Zacks Research raised shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 6th. Finally, Cantor Fitzgerald upped their price objective on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an "overweight" rating in a research note on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Supernus Pharmaceuticals has an average rating of "Moderate Buy" and an average price target of $62.83.

Supernus Pharmaceuticals Trading Down 1.0%

Shares of NASDAQ SUPN opened at $43.53 on Friday. The stock has a market cap of $2.53 billion, a P/E ratio of -22.67, a P/E/G ratio of 0.81 and a beta of 0.56. Supernus Pharmaceuticals, Inc. has a twelve month low of $42.45 and a twelve month high of $59.68. The stock has a 50 day moving average of $46.69 and a two-hundred day moving average of $48.41.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last announced its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%.The business had revenue of $219.06 million for the quarter, compared to analyst estimates of $205.31 million. During the same quarter last year, the company posted $0.40 EPS. Supernus Pharmaceuticals's quarterly revenue was up 32.4% on a year-over-year basis. As a group, research analysts predict that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source